EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC-ND 4.0

Stereotactic Prostate Cancer Ablative Re‐Irradiation: A Systematic Review and Meta‐Analysis (SPARE)

Andre G Gouveia iD, Jody Tao iD, Gregory Pond iD, Kevin Dong iD, Allison Ye iD, Arthur A Rosa iD, Daniel M Palhares, Conrad J Q Villafuerte, Paola Anselmo, Fabio Y Moraes iD, Fabio Arcidiacono, Robert Olson iD und 1 weitere

The Prostate · 2026-12 · 86 (16) · 1556-1568

DOI: 10.1002/pros.70233 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift The Prostate, online erschienen am 23.08.2026. Verfasst von Andre G Gouveia und 12 weiteren Autor:innen. Beteiligte Einrichtung: McMaster University, Hamilton, Canada. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Radiosurgery, Re-Irradiation, Neoplasm Recurrence, Local. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Stereotactic ablative radiotherapy (SABR) is emerging as an alternative treatment for patients with locally recurrent prostate cancer after previous radiation. This approach allows for precise target coverage while limiting toxicity to surrounding organs. However, reported outcomes following re‐irradiation of the prostate with SABR remain variable. This systematic review and meta‐analysis therefore evaluated the efficacy and toxicity of prostate re‐irradiation with SABR.

Methods

A systematic review and meta‐analysis compliant with PRISMA guidelines was conducted to evaluate studies of SABR for local re‐irradiation of prostate cancer. Random‐effects models were employed to pool biochemical recurrence‐free survival (BRFS), local relapse‐free survival (LRFS), metastasis‐free survival (MFS), and gastrointestinal (GI) and genitourinary (GU) toxicities after SABR re‐irradiation. Outcomes were pooled as proportions using the Freeman–Tukey double arcsine transformation, and heterogeneity was assessed using I 2 . Statistical analyses were performed using Stata version 19.5.

Results

A total of 30 treatment cohorts from 29 studies, including 1099 patients, were analysed. The pooled rates for 2‐year BRFS, LRFS, and MFS were 62.5% (95% CI, 54.1–70.6%; I 2 = 81.9%), 89.9% (95% CI, 80.6–96.5%; I 2 = 85.5%), and 84.6% (95% CI, 77.3–90.7%; I 2 = 77.8%), respectively. Acute severe side effects were rare, with pooled rates of grade 3–4 GI toxicities of 0.7% (95% CI, 0.3–1.4%; I 2 = 0%) and grade 3–4 GU toxicities of 1.1% (95% CI, 0.6%–1.9%; I 2 = 0%). Late grade 3–4 toxicity also remained low, with pooled GI and GU rates of 1.0% (95% CI, 0.5–1.7%; I 2 = 0%) and 3.3% (95% CI, 2.0–5.0%; I 2 = 46.1%), respectively.

Conclusion

Prostate re‐irradiation with SABR is associated with favourable short‐ and intermediate‐term oncologic outcomes, including high local control and metastasis‐free survival, with acceptable toxicity. The heterogeneity observed across studies and the very low certainty of evidence encourage the inclusion of these patients in prospective trials or registries to improve patient selection, dose–fractionation strategies, and long‐term outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsRadiosurgeryRe-IrradiationNeoplasm Recurrence, LocalMaleHumansDisease-Free SurvivalTreatment Outcome

Stichwörter der Autor:innen

Stereotactic ablative radiotherapy (SABR)Stereotactic body radiotherapy (SBRT)local recurrencemeta‐analysisprostate cancerre‐irradiationtoxicity

Autor:innen und Institutionen

  • McMaster University, Hamilton, Canada.
  • The University of British Columbia, Vancouver, Canada.
  • Latin America Cooperative Oncology Group (LACOG), Porto Alegre, Brazil.
  • Department of Radiation Oncology, BC Cancer Centre for the North, Prince George, Canada.
  • Radiotherapy Department, Hospital Santa Izabel, Salvador, Brazil.
  • Ateneo School of Medicine and Public Health, Manila, Philippines.

ORCID-Profile: Andre G Gouveia, Jody Tao, Gregory Pond, Kevin Dong, Allison Ye, Arthur A Rosa, Fabio Y Moraes, Robert Olson

Zitieren

APA

Gouveia, A. G., Tao, J., Pond, G., Dong, K., Ye, A., Rosa, A. A., Palhares, D. M., Villafuerte, C. J. Q., Anselmo, P., Moraes, F. Y., Arcidiacono, F., Olson, R., & Tsakiridis, T. (2026). Stereotactic Prostate Cancer Ablative Re‐Irradiation: A Systematic Review and Meta‐Analysis (SPARE). The Prostate, 86(16), 1556-1568. https://doi.org/10.1002/pros.70233

Vancouver

Gouveia AG, Tao J, Pond G, Dong K, Ye A, Rosa AA, et al. Stereotactic Prostate Cancer Ablative Re‐Irradiation: A Systematic Review and Meta‐Analysis (SPARE). The Prostate. 2026;86(16):1556-1568. doi:10.1002/pros.70233

BibTeX
@article{Gouveia2026,
  author = {Gouveia, Andre G and Tao, Jody and Pond, Gregory and Dong, Kevin and Ye, Allison and Rosa, Arthur A and Palhares, Daniel M and Villafuerte, Conrad J Q and Anselmo, Paola and Moraes, Fabio Y and Arcidiacono, Fabio and Olson, Robert and Tsakiridis, Theodoros},
  title = {Stereotactic Prostate Cancer Ablative Re‐Irradiation: A Systematic Review and Meta‐Analysis (SPARE)},
  journal = {The Prostate},
  year = {2026},
  volume = {86},
  number = {16},
  pages = {1556--1568},
  doi = {10.1002/pros.70233}
}
Kostenlos starten →